Datasheet

生物学的記述

Specificity	DARPP32 Antibody [G9D16] detects endogenous levels of total DARPP32 protein.
Background	DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, PPP1R1B) is a cytosolic, intrinsically disordered protein highly enriched in neostriatal medium spiny neurons (MSNs), where it integrates dopaminergic and glutamatergic signals crucial for basal ganglia function. Its flexible, unstructured nature enables multisite phosphorylation at key residues, Thr34 (PKA site, mediating PP1 inhibition), Thr75 (CDK5 site, inhibiting PKA), Ser102 (CK2 site, enhancing PKA efficacy), and Ser137 (CK1 site, modulating PP2B sensitivity), allowing combinatorial phospho-states that finely tune kinase and phosphatase balance without the need for rigid domains. Phosphorylation at Thr34 by D1R/cAMP/PKA turns DARPP-32 into a potent PP1 inhibitor, amplifying PKA-dependent phosphorylation of targets such as AMPA receptors, CREB, and histone H3, thereby potentiating striatal output, synaptic plasticity, and reward-related behaviors; in contrast, Thr75 phosphorylation by CDK5 inhibits PKA, counteracting dopamine effects, while Ser137 phosphorylation introduces timing-dependent integration of cAMP and Ca²⁺ signals via feedforward loops. This bidirectional, combinatorial regulation underlies MSN pathway excitability, long-term synaptic plasticity, and complex motivated behaviors. DARPP-32 is implicated in addiction (upregulated with psychostimulant use), Parkinson’s disease (D2-dependent dephosphorylation deficits), schizophrenia (Thr75 polymorphism-associated), depression, and frontostriatal cognitive impairment.

Specificity

DARPP32 Antibody [G9D16] detects endogenous levels of total DARPP32 protein.

Background

DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, PPP1R1B) is a cytosolic, intrinsically disordered protein highly enriched in neostriatal medium spiny neurons (MSNs), where it integrates dopaminergic and glutamatergic signals crucial for basal ganglia function. Its flexible, unstructured nature enables multisite phosphorylation at key residues, Thr34 (PKA site, mediating PP1 inhibition), Thr75 (CDK5 site, inhibiting PKA), Ser102 (CK2 site, enhancing PKA efficacy), and Ser137 (CK1 site, modulating PP2B sensitivity), allowing combinatorial phospho-states that finely tune kinase and phosphatase balance without the need for rigid domains. Phosphorylation at Thr34 by D1R/cAMP/PKA turns DARPP-32 into a potent PP1 inhibitor, amplifying PKA-dependent phosphorylation of targets such as AMPA receptors, CREB, and histone H3, thereby potentiating striatal output, synaptic plasticity, and reward-related behaviors; in contrast, Thr75 phosphorylation by CDK5 inhibits PKA, counteracting dopamine effects, while Ser137 phosphorylation introduces timing-dependent integration of cAMP and Ca²⁺ signals via feedforward loops. This bidirectional, combinatorial regulation underlies MSN pathway excitability, long-term synaptic plasticity, and complex motivated behaviors. DARPP-32 is implicated in addiction (upregulated with psychostimulant use), Parkinson’s disease (D2-dependent dephosphorylation deficits), schizophrenia (Thr75 polymorphism-associated), depression, and frontostriatal cognitive impairment.

使用情報

Application

WB, IP, IHC, IF

Dilution

WB	IP	IHC	IF
1:1000	1:50	1:200	1:400

Reactivity

Mouse, Rat

Source

Rabbit Monoclonal Antibody

MW

32 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/17194217/
https://pubmed.ncbi.nlm.nih.gov/21927600/

DARPP32 Antibody [G9D16]

生物学的記述

使用情報

References

Application Data